SANSERT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sansert, and when can generic versions of Sansert launch?
Sansert is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SANSERT is methysergide maleate. Additional details are available on the methysergide maleate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SANSERT?
- What are the global sales for SANSERT?
- What is Average Wholesale Price for SANSERT?
Summary for SANSERT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,618 |
| DailyMed Link: | SANSERT at DailyMed |
Recent Clinical Trials for SANSERT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
US Patents and Regulatory Information for SANSERT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SANSERT | methysergide maleate | TABLET;ORAL | 012516-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
